NASDAQ

AMGEN, INC (AMGN)

Currency USD

Company Overview

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Contact Details

Address
ONE AMGEN CENTER DRIVE
City
THOUSAND OAKS
State
CA
Country
USA
Zip Code
91320
Phone Number
805-447-1000
Website
-

Financial Highlights

Day Range

The price range a stock has traded at during the most recent trading period.

-
-
5 Day Range

The price range a stock has traded at during the previous 5 days.

-
-
3 Month Range

The price range a stock has traded at during the previous 3 months.

-
-
52 Week Range

The price range a stock has traded at during the previous 52 weeks.

-
-
Previous Close

The closing price of a stock from the previous day.

-
Open

The price of the stock at the start of today’s market opening.

-
Bid

The amount of money a trader is willing to pay per share for a given stock. 

x
-
Ask

The amount of money a seller wants per share of a given stock.

x
-
Volume

The number of shares traded in a given period. This number illustrates the active interest in the stock at any time.

-
Avg. Volume

The average number of shares traded in a given day.

-
Dividend Yield

A company's annual dividend expressed as a percentage of its current stock price.

-
Recent Dividend

The value a shareholder receives from a company they are invested in for holding their shares.

-
Beta

A measurement of the stock’s volatility in comparison to the market as a whole.

-

Shareholding

Shares Outstanding

Number of shares currently held by investors, including restricted shares owned by the company's officers and insiders.

-
Insider Shareholders

The percentage of shares owned by any officer or board director of the company, including their related or affiliated individuals, families, entities and trusts.

-
Institutional Shareholders

The percentage of shares owned by an institution such as a mutual fund, bank or insurance company.

-
Market Cap

The market value of a company’s outstanding shares. It is used as a measurement tool to determine how large a company is.

-
Revenue TTM

The amount of money a company has made for the trailing twelve-month period.

-
Net Income TTM

A measurement of how much profit they are retaining for the trailing twelve-month period.

-
P/E Ratio

The Price to Earnings (P/E) ratio, is calculated by dividing the stock's most recent share price by the sum of the diluted earnings per share.

-
EPS TTM

Earnings Per Share (EPS) TTM is a company's profit for the trailing twelve-month period divided by its number of common outstanding shares.

-
1 Year Return

A measurement of how much the stock has increased or decreased in the last year.

-

There is no stock data currently available for this time period, please select another option.

Please wait, gathering market data...

Latest News

View More
News |

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

View More
News |

Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon

View More
News |

Asian shares mostly higher ahead of Fed rate hike decision

View More
News |

Amgen to buy Horizon Therapeutics in $26.4B deal

View More